Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.12
(
0.66%
)
Bitcoin
70,507.00
(
0.87%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 97214

Sunday, 06/13/2010 9:00:40 PM

Sunday, June 13, 2010 9:00:40 PM

Post# of 257262
Good catch, ghmm! This is a notable trial design insofar as BI is sticking with ribavirin in all trial arms. I presume BI has replicon data showing that the BI 207127 + BI 201335 combination is strongly boosted by ribavirin.

The clinicaltrials.gov entry says, “Study First Received: May 3, 2010,” which explains why BI’s program is not included in #msg-51233708.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today